The Biopharmaceuticals Market is predicted to reach US$ by 2030 from US$ 401.32 billion in 2021, and to grow at a CAGR of 7.5% between the forecast period 2022 to 2030.
The research report includes specific segments by Products/Type and by Application, by region (country). This study provides information about the sales and revenue of each segment during the historic and forecasted period from 2022 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
This report also provides information on the prevalent market dynamics such as market drivers and restraints and future growth opportunities anticipated within the forecast period. The report includes competitive landscape of the top players operating in the market for the base year 2021. The company profiles section of the report studies the position of the major market players based on considerations such as business profile, product/service portfolio, trailing annual revenues, and recent strategies.
Major segmentation covered in this report is as follows:
By Product Type (Monoclonal Antibody, Interferons, Growth & Coagulation Factors, Recombinant Proteins, Hormones, Vaccines, Cell & Gene Therapies, and Others), by Therapeutic Application (Oncology, Immunology, Cardiovascular Diseases, Neurological Diseases, Metabolic Diseases, Blood Disorder, and Others), by End User (Hospital & Retail Pharmacies, Biopharma Companies, Diagnostic Labs, and Clinical Research Organizations)
By Region
North America, Europe, Asia Pacific, and the Rest of the World
Major market players covered in this study are
Pfizer, Inc., F. Hoffmann-La Roche Ltd., AbbVie, Inc., Johnson & Johnson Private, Ltd., Novartis AG, Bayer AG, Abbott Laboratories Inc., Amgen Inc, Eli Lilly and Company, Biogen Inc., Biocon Ltd., Thermo Fisher Scientific Inc
1. INTRODUCTION
1. Market Ecosystem
2. Timeline Under Consideration
1. Historical Years - 2020
2. Base Year - 2021
3. Forecasted Years - 2022 to 2030
3. Currency Used in the Report
2. RESEARCH METHODOLOGY
1. Research Approach
2. Data Collection Methodology
3. Data Sources
1. Secondary Sources
2. Primary Sources
4. Market Estimation Approach
1. Bottom Up
2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
3. PREMIUM INSIGHTS
1. Current Market Trend (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2021)
4. MARKET DYNAMICS
1. Drivers
2. Restraints
3. Opportunities
5. GLOBAL Biopharmaceuticals - ANALYSIS & FORECAST, BY PRODUCT
Product 1, Product 2
6. GLOBAL Biopharmaceuticals - ANALYSIS & FORECAST, BY TYPE
Type 1, Type 2
1. GLOBAL Biopharmaceuticals - ANALYSIS & FORECAST, BY END USER
End User 1, End User 2
2. GLOBAL Biopharmaceuticals - ANALYSIS & FORECAST, BY REGION
North America Biopharmaceuticals
1. North America Biopharmaceuticals , by Country
1. US
2. Canada
1. North America Biopharmaceuticals , by Product
2. North America Biopharmaceuticals , by Type
3. North America Biopharmaceuticals , by Gender
4. North America Biopharmaceuticals , by Sales Channel
3. Europe Biopharmaceuticals
1. Europe Biopharmaceuticals , by Country/Region
1. Germany
2. UK
3. France
4. Rest of Europe
2. Europe Biopharmaceuticals , by Product
3. Europe Biopharmaceuticals , by Type
4. Europe Biopharmaceuticals , by Gender
5. Europe Biopharmaceuticals , by Sales Channel
4. Asia Pacific Biopharmaceuticals
1. Asia Pacific Biopharmaceuticals , by Country/Region
1. China
2. Japan
3. India
4. Rest of Asia Pacific
2. Asia Pacific Biopharmaceuticals , by product
3. Asia Pacific Biopharmaceuticals , by Type
4. Asia Pacific Biopharmaceuticals , by Gender
5. Asia Pacific Biopharmaceuticals , by Sales Channel
5. Rest of the World Biopharmaceuticals
1. Rest of the World Biopharmaceuticals , by Region
1. Latin America
2. Middle East & Africa
2. Rest of the World Biopharmaceuticals , by Product
3. Rest of the World Biopharmaceuticals , by Type
4. Rest of the World Biopharmaceuticals , by Gender
5. Rest of the World Biopharmaceuticals , by Sales Channel
2. COMPANY PROFILES
Company 1, Company 32